APA (7th ed.) Citation

Hasni, S., Gupta, S., Davis, M., Poncio, E., Temesgen‐Oyelakin, Y., Joyal, E., . . . Rivera, J. (2019). Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti‐IgE Monoclonal Antibody in Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.), 71(7), 1135-1140. https://doi.org/10.1002/art.40828

Chicago Style (17th ed.) Citation

Hasni, Sarfaraz, et al. "Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti‐IgE Monoclonal Antibody in Systemic Lupus Erythematosus." Arthritis & Rheumatology (Hoboken, N.J.) 71, no. 7 (2019): 1135-1140. https://doi.org/10.1002/art.40828.

MLA (9th ed.) Citation

Hasni, Sarfaraz, et al. "Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti‐IgE Monoclonal Antibody in Systemic Lupus Erythematosus." Arthritis & Rheumatology (Hoboken, N.J.), vol. 71, no. 7, 2019, pp. 1135-1140, https://doi.org/10.1002/art.40828.